Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma

Jiazhong Jiang, Thomas M. Ulbright, Shaobo Zhang, George J. Eckert, Chinghai Kao, Thomas A. Gardner, Michael O. Koch, John N. Eble, Liang Cheng

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND. Fas is a Type I membrane receptor of the tumor necrosis factor/nerve growth factor family. On binding to Fas ligand, a Type II transmembrane protein, the Fas/Fas ligand complex, induces apoptosis in target cells. Dysregulation of Fas and Fas ligand expression has been found in some malignant neoplasms. METHODS. Using immunohistochemical analysis, the authors studied the expression of Fas and Fas ligand in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia (PIN), and adjacent benign prostate tissue from 95 radical prostatectomy specimens. RESULTS. The percentage of cells that stained positively with Fas in benign prostate tissue (mean, 2%) was statistically significantly lower compared with that in prostatic intraepithelial neoplasia (mean, 13%; P = 0.0014) and prostatic adenocarcinoma (mean, 31%; P = 0.0001). The staining intensity of Fas was significantly less in benign prostate tissue compared with the staining intensity in PIN and prostatic adenocarcinoma. The percentage of cells that stained positively with Fas ligand in benign prostate tissue (mean, 13%) was statistically significantly lower compared with that in PIN (mean, 47%; P = 0.0001) and in prostatic adenocarcinoma (mean, 53%; P = 0.0001). The staining intensity of Fas ligand was significantly less in benign prostate tissue compared with that in PIN and prostatic adenocarcinoma. CONCLUSIONS. Data from the current study indicate that Fas/Fas ligand is elevated in prostatic malignancy, suggesting that Fas-mediated apoptosis may be a potential target for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)296-300
Number of pages5
JournalCancer
Volume95
Issue number2
DOIs
StatePublished - Jul 15 2002

Fingerprint

Prostatic Intraepithelial Neoplasia
Fas Ligand Protein
Adenocarcinoma
Prostate
Staining and Labeling
Apoptosis
Receptors, Tumor Necrosis Factor, Type I
Nerve Growth Factor
Prostatectomy
Neoplasms
Membranes

Keywords

  • Adenocarcinoma
  • Biomarkers
  • Fas
  • Fas ligand
  • Neoplasms
  • Prostate
  • Prostatic intraepithelial neoplasia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. / Jiang, Jiazhong; Ulbright, Thomas M.; Zhang, Shaobo; Eckert, George J.; Kao, Chinghai; Gardner, Thomas A.; Koch, Michael O.; Eble, John N.; Cheng, Liang.

In: Cancer, Vol. 95, No. 2, 15.07.2002, p. 296-300.

Research output: Contribution to journalArticle

@article{070cc4263a484610acacf000e5c9272a,
title = "Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma",
abstract = "BACKGROUND. Fas is a Type I membrane receptor of the tumor necrosis factor/nerve growth factor family. On binding to Fas ligand, a Type II transmembrane protein, the Fas/Fas ligand complex, induces apoptosis in target cells. Dysregulation of Fas and Fas ligand expression has been found in some malignant neoplasms. METHODS. Using immunohistochemical analysis, the authors studied the expression of Fas and Fas ligand in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia (PIN), and adjacent benign prostate tissue from 95 radical prostatectomy specimens. RESULTS. The percentage of cells that stained positively with Fas in benign prostate tissue (mean, 2{\%}) was statistically significantly lower compared with that in prostatic intraepithelial neoplasia (mean, 13{\%}; P = 0.0014) and prostatic adenocarcinoma (mean, 31{\%}; P = 0.0001). The staining intensity of Fas was significantly less in benign prostate tissue compared with the staining intensity in PIN and prostatic adenocarcinoma. The percentage of cells that stained positively with Fas ligand in benign prostate tissue (mean, 13{\%}) was statistically significantly lower compared with that in PIN (mean, 47{\%}; P = 0.0001) and in prostatic adenocarcinoma (mean, 53{\%}; P = 0.0001). The staining intensity of Fas ligand was significantly less in benign prostate tissue compared with that in PIN and prostatic adenocarcinoma. CONCLUSIONS. Data from the current study indicate that Fas/Fas ligand is elevated in prostatic malignancy, suggesting that Fas-mediated apoptosis may be a potential target for therapeutic intervention.",
keywords = "Adenocarcinoma, Biomarkers, Fas, Fas ligand, Neoplasms, Prostate, Prostatic intraepithelial neoplasia",
author = "Jiazhong Jiang and Ulbright, {Thomas M.} and Shaobo Zhang and Eckert, {George J.} and Chinghai Kao and Gardner, {Thomas A.} and Koch, {Michael O.} and Eble, {John N.} and Liang Cheng",
year = "2002",
month = "7",
day = "15",
doi = "10.1002/cncr.10674",
language = "English (US)",
volume = "95",
pages = "296--300",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma

AU - Jiang, Jiazhong

AU - Ulbright, Thomas M.

AU - Zhang, Shaobo

AU - Eckert, George J.

AU - Kao, Chinghai

AU - Gardner, Thomas A.

AU - Koch, Michael O.

AU - Eble, John N.

AU - Cheng, Liang

PY - 2002/7/15

Y1 - 2002/7/15

N2 - BACKGROUND. Fas is a Type I membrane receptor of the tumor necrosis factor/nerve growth factor family. On binding to Fas ligand, a Type II transmembrane protein, the Fas/Fas ligand complex, induces apoptosis in target cells. Dysregulation of Fas and Fas ligand expression has been found in some malignant neoplasms. METHODS. Using immunohistochemical analysis, the authors studied the expression of Fas and Fas ligand in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia (PIN), and adjacent benign prostate tissue from 95 radical prostatectomy specimens. RESULTS. The percentage of cells that stained positively with Fas in benign prostate tissue (mean, 2%) was statistically significantly lower compared with that in prostatic intraepithelial neoplasia (mean, 13%; P = 0.0014) and prostatic adenocarcinoma (mean, 31%; P = 0.0001). The staining intensity of Fas was significantly less in benign prostate tissue compared with the staining intensity in PIN and prostatic adenocarcinoma. The percentage of cells that stained positively with Fas ligand in benign prostate tissue (mean, 13%) was statistically significantly lower compared with that in PIN (mean, 47%; P = 0.0001) and in prostatic adenocarcinoma (mean, 53%; P = 0.0001). The staining intensity of Fas ligand was significantly less in benign prostate tissue compared with that in PIN and prostatic adenocarcinoma. CONCLUSIONS. Data from the current study indicate that Fas/Fas ligand is elevated in prostatic malignancy, suggesting that Fas-mediated apoptosis may be a potential target for therapeutic intervention.

AB - BACKGROUND. Fas is a Type I membrane receptor of the tumor necrosis factor/nerve growth factor family. On binding to Fas ligand, a Type II transmembrane protein, the Fas/Fas ligand complex, induces apoptosis in target cells. Dysregulation of Fas and Fas ligand expression has been found in some malignant neoplasms. METHODS. Using immunohistochemical analysis, the authors studied the expression of Fas and Fas ligand in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia (PIN), and adjacent benign prostate tissue from 95 radical prostatectomy specimens. RESULTS. The percentage of cells that stained positively with Fas in benign prostate tissue (mean, 2%) was statistically significantly lower compared with that in prostatic intraepithelial neoplasia (mean, 13%; P = 0.0014) and prostatic adenocarcinoma (mean, 31%; P = 0.0001). The staining intensity of Fas was significantly less in benign prostate tissue compared with the staining intensity in PIN and prostatic adenocarcinoma. The percentage of cells that stained positively with Fas ligand in benign prostate tissue (mean, 13%) was statistically significantly lower compared with that in PIN (mean, 47%; P = 0.0001) and in prostatic adenocarcinoma (mean, 53%; P = 0.0001). The staining intensity of Fas ligand was significantly less in benign prostate tissue compared with that in PIN and prostatic adenocarcinoma. CONCLUSIONS. Data from the current study indicate that Fas/Fas ligand is elevated in prostatic malignancy, suggesting that Fas-mediated apoptosis may be a potential target for therapeutic intervention.

KW - Adenocarcinoma

KW - Biomarkers

KW - Fas

KW - Fas ligand

KW - Neoplasms

KW - Prostate

KW - Prostatic intraepithelial neoplasia

UR - http://www.scopus.com/inward/record.url?scp=0037099557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037099557&partnerID=8YFLogxK

U2 - 10.1002/cncr.10674

DO - 10.1002/cncr.10674

M3 - Article

C2 - 12124829

AN - SCOPUS:0037099557

VL - 95

SP - 296

EP - 300

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -